Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial
JAMA Oncol 2023 Oct 26;[EPub Ahead of Print], S Oudard, R Ratta, E Voog, P Barthelemy, A Thiery-Vuillemin, M Bennamoun, A Hasbini, K Aldabbagh, C Saldana, E Sevin, E Amela, G Von Amsberg, N Houede, D Besson, S Feyerabend, M Boegemann, D Pfister, M Schostak, O Huillard, F Di Fiore, A Quivy, C Lange, L Phan, H Belhouari, Y Tran, S Kotti, C HelisseyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.